Vir Cuts Losses as Hepatitis Delta Trial Nears

Cash funding into 2028 gives the company's Phase 3 chronic hepatitis delta program time to report topline results.

Updated on Nov. 5, 2026 in Biotech

Bold flat-color editorial illustration of a single amber laboratory vial on a cream field beside a small stack of coins. — Vir Biotechnology reported a third-quarter net loss of $96.3 million, narrowed by lower research spending as it funds its Phase 3 hepatitis delta program into 2028. AI Illustration. Upload story photo >

Vir Biotechnology reported a third-quarter net loss of $96.3 million, or $0.57 per share, for the quarter ended Sept. 30. The company's results are reported financial figures; its Phase 3 chronic hepatitis delta program remains in development and has not reached market.

Why it matters

The narrower loss reflects lower research and development spending, which fell to $80 million from $151.5 million a year earlier, after a $75 million milestone expense in the prior-year quarter and collaboration cost recoveries in the latest one. Vir's runway into the second half of 2028 gives its pipeline, including the ECLIPSE 1 Phase 3 trial, time to report data.

Vir reported a $96.3 million third-quarter net loss, down from $163.1 million a year earlier, with research and development costs of $80 million against $151.5 million. The filing records these as reported financial figures and does not report clinical efficacy results, which remain pending the ECLIPSE 1 trial.

The players

Vir Biotechnology

A clinical-stage biotechnology company developing antiviral and immunotherapy candidates, including the elebsiran and tobevibart programs for chronic hepatitis delta.

The details

Vir's research and development spending is the largest driver of its losses, and the quarter's drop came from two items: a $75 million milestone expense booked a year earlier, and collaboration cost recoveries, which are reimbursements from partners that offset the company's own spending. Higher manufacturing costs partly offset that decline. The company's cash position of about $901.3 million is what funds these ongoing trial and development costs.

Sept. 30, 2026: Quarter end for the reported $96.3 million net loss.
Fourth quarter of 2026: Expected topline data from the ECLIPSE 1 Phase 3 trial.
Second half of 2028: Expected end of the funding runway from current cash and investments.

The Tech Race

Vir's hepatitis delta program is judged against other development efforts in chronic viral disease, where a Phase 3 readout is the decisive test. The company's spending decline and extended runway position it to reach that readout in the fourth quarter of 2026.

Patients with chronic hepatitis delta do not gain access to elebsiran or tobevibart from these results, since the drugs are still in Phase 3 testing. The next practical checkpoint is the ECLIPSE 1 topline readout expected in the fourth quarter of 2026.

The takeaway

Vir's spending decline shows a narrowing cost base ahead of a major trial. Watch the fourth-quarter 2026 topline data from ECLIPSE 1, which will show whether the hepatitis delta candidates succeed in Phase 3.

What happens next

Vir expects topline data from the ECLIPSE 1 Phase 3 trial in the fourth quarter of 2026, which will show whether elebsiran and tobevibart meet their primary endpoint for chronic hepatitis delta.